EVOS S1000 Review UK 2026: Multiplex Tissue Imaging

What Is the EVOS S1000 Spatial Imaging System?

The Invitrogen EVOS S1000 Spatial Imaging System is a slide-based fluorescence and brightfield microscope launched by Thermo Fisher Scientific in 2025 for spatial biology and tissue proteomics. Unlike the EVOS M5000 and M7000 — which are inverted cell-culture imagers — the S1000 is built to scan stained tissue sections on standard glass slides and generate multiplexed images with spectral unmixing.

Its headline claim is up to 9-plex fluorescence imaging in a single tissue section. That means researchers can label nine different proteins or markers simultaneously, capture the slide in one automated run, and computationally separate the fluorophores even when their emission spectra overlap. For cancer microenvironment studies, immuno-oncology and biomarker discovery, this kind of multiplexing turns a serial-section experiment into a single, spatially resolved dataset.

Why this matters to UK scientists: spatial proteomics is moving from specialist core facilities into mainstream cancer, immunology and pathology research. Systems that combine automated slide handling, spectral multiplexing and straightforward analysis software lower the barrier to entry and reduce the need to send every project to a spatial-omics core lab.

EVOS S1000 at a glance

• Slide-based tissue imaging system
• Multiplex spectral fluorescence up to 9-plex
• Automated scanning and tiling
• Brightfield and fluorescence overlay
• Designed for spatial proteomics and tumour microenvironment research

View EVOS S1000 on Thermo Fisher UK

Technical Rationale: What the S1000 Does Well

1. Spectral multiplexing on fixed tissue

Traditional fluorescence microscopy is limited by filter sets: one excitation/emission pair per channel, and panels rarely exceed four or five markers before spectral overlap becomes unmanageable. Spectral systems capture the full emission profile of each fluorophore and use linear unmixing to recover individual signals. The S1000 applies this approach to tissue slides, enabling larger antibody panels without the cyclic staining protocols used by some CODEX or imaging mass-cytometry workflows.

2. Slide-based, not plate-based

The S1000 is optimised for standard histology slides. That makes it a natural addition for pathology, cancer research and translational labs that already produce FFPE or frozen sections. It does not require the multiwell plate format of high-content screening, so it can image clinical tissue arrays, tissue microarrays and serial sections with minimal workflow change.

3. Integration with the EVOS software ecosystem

Like other EVOS systems, the S1000 uses the familiar EVOS interface. Labs already running an EVOS M5000 or M7000 for cell culture do not have to learn a second acquisition environment to add tissue imaging. Images can be exported as standard TIFF for downstream analysis in QuPath, Fiji, CellProfiler or AI pipelines.

4. Throughput for small-to-medium panels

While it is not a whole-slide scanner, the S1000 is designed for targeted regions of interest rather than full-slide pathology screening. For research projects with defined marker panels — for example, CD3/CD8/PD-1/PD-L1 tumour immune profiling — it offers a middle ground between manual fluorescence microscopy and high-end whole-slide multiplex platforms.

EVOS S1000 vs CellInsight CX5 vs EVOS M7000

The S1000 and CX5 are not competitors in the same workflow; they are complementary platforms. A UK cancer research group might use the S1000 to characterise marker expression across a tumour tissue bank, then use the CX5 or EVOS M7000 to run functional assays in cell lines or organoids derived from the same samples.

For a deeper comparison of EVOS systems, see our EVOS M7000 review and EVOS S1000 vs M7000 spatial biology guide.

Who Should Consider the EVOS S1000 in the UK?

• Cancer and immuno-oncology labs mapping immune infiltrates, checkpoint expression or stromal markers in tissue sections.
• Pathology and translational research groups adding multiplex immunofluorescence to existing H&E or IHC workflows.
• Core facilities that need a mid-tier spectral tissue imager between a manual fluorescence microscope and a high-end whole-slide scanner.
• Groups already invested in EVOS who want to extend the platform into tissue imaging without buying a separate software ecosystem.

Who should look elsewhere? Labs needing deep optical sectioning in thick cleared tissue, live-cell time-lapse, or fully automated high-throughput screening should consider confocal, light-sheet or CellInsight CX7/CX5 platforms instead.

Recent Publications and Resources

Multiplex tissue imaging and spatial proteomics are now mainstream in cancer biology. The references below explain why slide-based multiplex systems such as the EVOS S1000 are relevant and what technical standards the field is converging on.

Frequently Asked Questions